Sivia Capital Partners LLC Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sivia Capital Partners LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 343 shares of the biopharmaceutical company’s stock after acquiring an additional 66 shares during the quarter. Sivia Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $244,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $37,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $39,000. Finally, Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on REGN shares. Bank of America reissued an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Oppenheimer decreased their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Leerink Partners restated a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,037.33.

Regeneron Pharmaceuticals Stock Up 1.9 %

Shares of Regeneron Pharmaceuticals stock traded up $13.43 on Monday, reaching $710.31. 1,022,090 shares of the company were exchanged, compared to its average volume of 787,123. The company has a market cap of $78.06 billion, a P/E ratio of 17.58, a price-to-earnings-growth ratio of 2.19 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock’s 50 day moving average price is $751.44 and its 200-day moving average price is $961.06.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.